Valuation: Glaukos Corporation

Market Cap 11B 9.54B 8.94B 8.15B 15.34B 1,050B 15.58B 105B 41.1B 526B 41.31B 40.41B 1,754B P/E 2026 *
-231x
P/E 2027 * 635x
Enterprise Value 10.83B 9.39B 8.8B 8.02B 15.1B 1,033B 15.34B 104B 40.44B 517B 40.65B 39.77B 1,726B EV / Sales 2026 *
15.7x
EV / Sales 2027 * 12.7x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week+9.48%
Current month+12.29%
1 month+22.58%
3 months+36.36%
6 months+71.01%
Current year+65.80%
1 week 172.22
Extreme 172.215
188.87
1 month 145.78
Extreme 145.7759
188.87
Current year 93.96
Extreme 93.96
188.87
1 year 73.16
Extreme 73.16
188.87
3 years 59.22
Extreme 59.22
188.87
5 years 33.33
Extreme 33.33
188.87
10 years 23.08
Extreme 23.075
188.87
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap.
07/08/26 Fiscal year

Chief Financial Officer

60,000 0.1046%
31/07/26 Sell

Director

-525 0.0009%
16/07/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%+9.48%+103.95%+153.63% 11B
-1.99%+0.79%-10.26%+19.41% 133B
+1.10%+0.68%-18.29%-0.05% 12.42B
-0.62%-1.78%-44.61%-67.34% 4.65B
-0.40%+4.21%-27.81%+43.11% 2.75B
-0.82%-2.08%-33.99%-77.07% 1.68B
+0.43%+1.02%-21.58%-11.67% 1.68B
+0.48%+1.10%-32.24%-33.76% 1.66B
-0.51%-7.26%-17.54%-56.81% 1.42B
Average -0.30%-1.17%-11.37%-3.40% 18.94B
Weighted average by Cap. -1.53%+2.65%-5.31%+22.26%

Financials

2026 *2027 *
Net sales 691M 599M 561M 512M 963M 65.92B 978M 6.61B 2.58B 33B 2.59B 2.54B 110B 842M 730M 684M 624M 1.17B 80.35B 1.19B 8.06B 3.14B 40.22B 3.16B 3.09B 134B
Net income -51.88M -44.97M -42.16M -38.44M -72.33M -4.95B -73.49M -496M -194M -2.48B -195M -191M -8.27B 18.93M 16.41M 15.38M 14.02M 26.38M 1.81B 26.81M 181M 70.69M 904M 71.05M 69.52M 3.02B
Net Debt -175M -152M -142M -130M -244M -16.69B -248M -1.67B -653M -8.35B -657M -642M -27.87B -273M -236M -222M -202M -380M -26.04B -386M -2.61B -1.02B -13.03B -1.02B -1B -43.48B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
13/08/26 US$187.32 +0.37% 269,898
12/08/26 US$186.63 +2.54% 754,151
11/08/26 US$182.00 +0.32% 723,323
10/08/26 US$181.42 +0.78% 646,071
07/08/26 US$180.02 +5.28% 768,790
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
186.63USD
Average target price
193.62USD
Spread / Average Target
+3.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock